Invitae Corporation (NVTA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Invitae Corporation (NVTA) trades at $0.02 with AI Score 50/100 (Grade B). Invitae Corporation is a medical genetics company focused on integrating genetic information into mainstream medicine. Market cap: $5.44M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for NVTA: NVTA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NVTA against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NVTA: the 1 perspectives are evenly split.
How is this calculated? →Invitae Corporation (NVTA) Healthcare & Pipeline Overview
Invitae Corporation integrates genetic information into healthcare, offering a range of genetic tests and digital health solutions. With a focus on hereditary cancer, cardiology, and rare diseases, Invitae serves patients, healthcare providers, and biopharma companies. The company operates in the competitive medical diagnostics and research sector.
What Is the Investment Thesis for NVTA?
Invitae Corporation operates in the rapidly evolving field of medical genetics, offering potential for significant growth. Key value drivers include the increasing adoption of genetic testing in clinical practice and the expansion of Invitae's test menu and digital health solutions. With a gross margin of 19.2%, there is room for improvement as the company scales its operations and optimizes its cost structure. Growth catalysts include ongoing partnerships with biopharma companies and the development of new genetic tests for various diseases. However, the company's negative profit margin of -601.6% and a market capitalization of $5.44M indicate substantial financial challenges. Investors should closely monitor Invitae's ability to achieve profitability and manage its debt levels. The company's beta of 1.59 suggests higher volatility compared to the broader market.
Based on FMP financials and quantitative analysis
NVTA Key Highlights
- Market capitalization of $5.44M reflects the company's current valuation in the market.
- Gross margin of 19.2% indicates the profitability of Invitae's genetic testing services before operating expenses.
- Profit margin of -601.6% highlights significant financial challenges and the need for improved cost management.
- Beta of 1.59 suggests higher volatility compared to the broader market, indicating potential for larger price swings.
- Invitae serves patients, healthcare providers, and biopharma companies, demonstrating a diversified customer base.
Who Are NVTA's Competitors?
NVTA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRE Prenetics Global Limited | $16.71 | -4.48% | $284.02M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.99 | +1.01% | $42.56M | 68 |
| TWST Twist Bioscience Corporation | $91.11 | -8.83% | $5.67B | 65 |
| ME 23andMe Holding Co. | $0.61 | +100.00% | $15.31M | 50 |
| BNGO Bionano Genomics, Inc. | $1.15 | -1.29% | $13.14M | 50 |
| ICLR ICON Public Limited Company | $168.72 | -1.30% | $12.92B | 50 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NVTA's Key Strengths?
- Comprehensive genetic test menu.
- Digital health solutions enhance user experience.
- Partnerships with biopharma companies.
- Extensive genetic database for research.
What Are NVTA's Weaknesses?
- Negative profit margin indicates financial challenges.
- High beta suggests higher market volatility.
- Reliance on partnerships for revenue generation.
- Intense competition in the genetic testing market.
What Could Drive NVTA Stock Higher?
- New partnerships with biopharma companies to develop companion diagnostics (2026 Q3).
- Expansion of the genetic test menu to include more rare diseases and oncology panels.
- Development and launch of new digital health solutions to improve patient engagement.
- International expansion into key European markets (2027 H1).
What Are the Key Risks for NVTA?
- Financial-distress signal — its Altman Z-Score of -23.09 sits in the distress zone (elevated bankruptcy risk).
- Regulatory changes impacting reimbursement for genetic testing services.
- Intense competition from established diagnostics companies.
- Data privacy and security breaches compromising patient information.
- Technological advancements rendering existing tests obsolete.
- Failure to achieve profitability and manage debt levels.
What Are the Growth Opportunities for NVTA?
- Expanding Test Menu: Invitae can grow by continually expanding its test menu to cover more genetic conditions and clinical areas. The market for genetic testing is projected to reach $25 billion by 2028, driven by advancements in sequencing technology and increasing demand for personalized medicine. By introducing new tests for rare diseases, oncology, and reproductive health, Invitae can attract new customers and increase revenue. Timeline: Ongoing.
- Digital Health Solutions: Invitae's digital health solutions offer a significant growth opportunity by improving the patient and provider experience. The market for digital health is expected to reach $660 billion by 2027. By developing user-friendly platforms for ordering tests, interpreting results, and integrating genetic information into clinical workflows, Invitae can enhance customer satisfaction and drive adoption. Timeline: Ongoing.
- Partnerships with Biopharma Companies: Collaborating with biopharmaceutical companies to develop companion diagnostics and support drug development efforts presents a substantial growth opportunity. The market for companion diagnostics is projected to reach $12 billion by 2025. By partnering with biopharma companies to identify patients who are likely to benefit from specific therapies, Invitae can generate revenue from testing services and contribute to the advancement of personalized medicine. Timeline: Ongoing.
- International Expansion: Expanding its geographic footprint into new international markets represents a significant growth opportunity for Invitae. The global market for genetic testing is growing rapidly, particularly in emerging economies. By establishing operations in Europe, Asia, and Latin America, Invitae can tap into new customer bases and diversify its revenue streams. Timeline: 2027-2030.
- Health Data Services: Leveraging its extensive genetic database to offer health data services to research institutions and pharmaceutical companies provides another avenue for growth. The market for healthcare data analytics is projected to reach $50 billion by 2028. By providing access to anonymized genetic data and analytical tools, Invitae can support research and development efforts and generate revenue from data licensing and consulting services. Timeline: Ongoing.
What Opportunities Does NVTA Have?
- Expanding test menu to cover more genetic conditions.
- Growing demand for personalized medicine and genetic testing.
- International expansion into new markets.
- Leveraging health data services for research and development.
What Threats Does NVTA Face?
- Regulatory changes and reimbursement policies.
- Competition from established diagnostics companies.
- Data privacy and security concerns.
- Technological advancements rendering existing tests obsolete.
What Are NVTA's Competitive Advantages?
- Comprehensive Test Menu: Offers a wide range of genetic tests across various clinical areas.
- Digital Health Solutions: Provides user-friendly platforms for ordering tests and interpreting results.
- Extensive Genetic Database: Leverages a large database of genetic information for research and development.
- Partnerships: Collaborates with biopharma companies and research institutions.
What Does NVTA Do?
Invitae Corporation, founded in 2010 and headquartered in San Francisco, California, is a medical genetics company focused on making genetic information accessible and integrated into mainstream medicine. Originally named Locus Development, Inc., the company rebranded as Invitae Corporation in 2012, signaling its commitment to innovation in genetic testing. Invitae offers a comprehensive suite of genetic tests across various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. These tests help healthcare providers diagnose, treat, and prevent diseases by providing critical genetic insights. In addition to its genetic testing services, Invitae provides digital health solutions designed to enhance the patient and provider experience. These solutions aim to streamline the process of ordering tests, interpreting results, and integrating genetic information into clinical decision-making. Invitae also offers health data services, leveraging its extensive genetic database to support research and development efforts for biopharmaceutical companies and other partners. The company serves a diverse range of customers, including patients, healthcare providers, biopharma companies, and research institutions, operating in the United States, Canada, and internationally. Invitae's mission is to improve healthcare outcomes by making genetic information more accessible and actionable for everyone.
What Products and Services Does NVTA Offer?
- Offers genetic tests for hereditary cancer, cardiology, neurology, and pediatrics.
- Provides genetic testing for oncology, metabolic conditions, and rare diseases.
- Integrates genetic information into mainstream medicine to improve healthcare.
- Develops digital health solutions to enhance the patient and provider experience.
- Offers health data services to biopharma companies and research institutions.
- Serves patients, healthcare providers, and other partners in the United States, Canada, and internationally.
How Does NVTA Make Money?
- Generates revenue from genetic testing services provided to patients and healthcare providers.
- Earns income from digital health solutions that streamline the testing process.
- Partners with biopharma companies to develop companion diagnostics and support drug development.
- Offers health data services, licensing anonymized genetic data to research institutions.
What Industry Does NVTA Operate In?
Invitae Corporation operates within the medical diagnostics and research industry, a sector experiencing rapid growth driven by technological advancements and increasing demand for personalized medicine. The market for genetic testing is expanding, fueled by the decreasing cost of sequencing and the growing awareness of the role of genetics in healthcare. The competitive landscape includes established players like Roche and smaller, specialized companies. Invitae aims to differentiate itself through its comprehensive test menu, digital health solutions, and partnerships with biopharma companies. The industry is subject to regulatory oversight and requires continuous innovation to stay ahead of the competition.
Who Are NVTA's Key Customers?
- Patients seeking genetic testing for various health conditions.
- Healthcare providers who order genetic tests for their patients.
- Biopharmaceutical companies that use genetic data for drug development.
- Research institutions conducting genetic research.
F-Score 4/9Financial Health
Invitae Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -23.09 places it in the distress zone, a signal of elevated financial risk.
Invitae Corporation (NVTA) Valuation Context
Valued at $5.44M, NVTA is classified as a micro-cap stock. Relative to its peer group, NVTA's quantitative score of 50/100 is below the peer average of 64/100.
Company Profile
Invitae Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Kenneth D. Knight. NVTA has traded publicly since 2015.
Net buyingInsider Activity
The most recent 7 insider filings for Invitae Corporation break down as 3 sales and 4 purchases. On net that is roughly 2.7M shares acquired (about $32K) — insiders putting money in tends to read as conviction.
NVTA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Comprehensive genetic test menu.
- Digital health solutions enhance user experience.
- Partnerships with biopharma companies.
- Extensive genetic database for research.
Bear Case
- Negative profit margin indicates financial challenges.
- High beta suggests higher market volatility.
- Reliance on partnerships for revenue generation.
- Intense competition in the genetic testing market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NVTA Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Mar 15, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Jun 14, 2022
NVTA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVTA.
Price Targets
Wall Street price target analysis for NVTA.
NVTA MoonshotScore
What does this score mean?
The MoonshotScore rates NVTA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kenneth D. Knight
CEO
Kenneth D. Knight serves as the Chief Executive Officer of Invitae Corporation, bringing extensive leadership experience in the healthcare and diagnostics industries. His background includes a proven track record of driving growth and innovation in complex organizations. Prior to joining Invitae, Knight held key leadership positions at leading healthcare companies, where he focused on strategic planning, operational excellence, and market expansion. His expertise spans across various areas, including genetic testing, diagnostics, and personalized medicine. Knight's leadership is characterized by a commitment to improving patient outcomes and advancing the field of medical genetics.
Track Record: Under Kenneth D. Knight's leadership, Invitae Corporation has focused on expanding its genetic testing services and enhancing its digital health solutions. Key achievements include forging strategic partnerships with biopharmaceutical companies and expanding the company's presence in key international markets. Knight has also overseen efforts to improve operational efficiency and reduce costs, while maintaining a focus on innovation and customer satisfaction. His strategic decisions have aimed to position Invitae as a leader in the rapidly evolving field of medical genetics.
Invitae Corporation Healthcare Stock: Key Questions Answered
What does Invitae Corporation do?
Invitae Corporation is a medical genetics company that integrates genetic information into mainstream medicine to improve healthcare. The company offers a range of genetic tests across various clinical areas, including hereditary cancer, cardiology, neurology, and rare diseases. Invitae also provides digital health solutions to enhance the patient and provider experience, making genetic testing more accessible and actionable. Additionally, the company offers health data services, leveraging its extensive genetic database to support research and development efforts for biopharmaceutical companies and other partners. Invitae's mission is to improve healthcare outcomes by making genetic information more accessible and affordable.
What do analysts say about NVTA stock?
Analyst consensus on Invitae Corporation (NVTA) stock is mixed, reflecting the company's financial challenges and growth opportunities. Key valuation metrics, such as market capitalization and price-to-sales ratio, are closely monitored. Growth considerations include the expansion of Invitae's test menu, partnerships with biopharma companies, and international expansion efforts. Analysts also focus on the company's ability to improve its gross margin and achieve profitability. The stock's beta of 1.59 suggests higher volatility compared to the broader market, indicating potential for larger price swings. Investors should conduct their own due diligence and consider their risk tolerance before investing in NVTA.
What are the main risks for NVTA?
Invitae Corporation faces several key risks that could impact its financial performance and growth prospects. These include regulatory changes affecting reimbursement for genetic testing services, intense competition from established diagnostics companies, and the potential for data privacy and security breaches. Additionally, technological advancements could render existing tests obsolete, requiring continuous innovation and investment in new technologies. The company's ability to achieve profitability and manage its debt levels is also a significant risk factor. Investors should carefully consider these risks before investing in Invitae.
What are the key factors to evaluate for NVTA?
Invitae Corporation (NVTA) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does NVTA data refresh on this page?
NVTA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NVTA's recent stock price performance?
Invitae Corporation (NVTA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive genetic test menu. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NVTA overvalued or undervalued right now?
Valuing Invitae Corporation (NVTA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NVTA?
Before investing in Invitae Corporation (NVTA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Financial metrics are subject to change based on market conditions and company performance.